MétaCan
Menu
Back to cohort

441 Reimagining bladder cancer immunotherapy: local non-viral gene delivery of DNA-encoded immune checkpoint inhibitors

2025· article· W4415898806 on OpenAlexaff
Martine Bail, David Lazure, Christine Zouki, Kristine S. Louis, Darius Bilimoria, Palig Khatcherian, Sarah Stevenson, Sahar Amirkhani, James C. Sullivan, Anthony Cheung

Bibliographic record

VenueRegular and Young Investigator Award Abstracts · 2025
Typearticle
Language
FieldMedicine
TopicBladder and Urothelial Cancer Treatments
Canadian institutionsCégep de Saint-Laurent
Fundersnot available
KeywordsBladder cancerImmune systemGeneImmune checkpointGene delivery

Abstract

fetched live from OpenAlex

Background enGene has developed Dually Derivatized Oligochitosan® (DDX), a non-viral, non-integrating gene delivery platform designed for local administration to the bladder mucosa via intravesical instillation (IVI). In an ongoing registrational trial ( NCT04752722), the DDX-formulated drug detalimogene voraplasmid is being evaluated for safety and efficacy in Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). The preliminary overall complete response (CR) rate is 71% (15/21) with a favorable safety/tolerability profile. To further leverage the potential of the DDX platform, enGene is developing novel formulations for bladder-localized expression of DNA-encoded monoclonal antibodies, specifically, immune checkpoint inhibitors (ICI) which are typically delivered intravenously or subcutaneously. This approach aims to retain antitumor efficacy while avoiding systemic toxicities associated with conventional ICI therapies.Methods Plasmids were designed to co-express the heavy and light chains of two ICI’s, nivolumab and pembrolizumab, using bicistronic single expression cassette or dual-promoter expression cassettes. These constructs were formulated with DDX and screened for in vitro expression and function in relevant cell lines, using paratope-specific and human PD-1/PD-L1 competitive immunoassays. In vivo expression duration, dose response, and systemic exposure were assessed in C57BL/6 mice after IVI. A custom paratope-specific immunoassay on the Meso Scale Discovery platform was used to quantify protein levels. Therapeutic efficacy of ICI-expressing DDX formulation is currently being evaluated in a humanized PD-1 murine orthotopic bladder cancer model.Results The expression constructs for pembrolizumab and nivolumab demonstrated dose-dependent expression in vitro. The PD-1/PD-L1 blocking potency of the expressed ICI was the same as the blocking activity of recombinant ICI from commercial suppliers, confirming their functional integrity. IVI of DDX-packaged nanoparticles containing the ICI-expressing plasmid in C57BL/6 mice led to sustained, dose-dependent expression in the bladder lasting over 28 days. Importantly, systemic exposure remained minimal—approximately 1,000-fold lower than that observed following intravenous administration of recombinant ICI at clinically relevant doses—highlighting the advantage of this localized delivery approach.Conclusions These data demonstrate the potential utility of the DDX platform for localized, sustained expression of DNA-encoded ICI monoclonal antibodies in the bladder with significantly reduced systemic exposure.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.257
Teacher spread0.247 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractno

Explore more

Same venueRegular and Young Investigator Award AbstractsSame topicBladder and Urothelial Cancer TreatmentsFrench-language works237,207